Analysis Group, Inc., Boston, Massachusetts, USA.
Pharmacoeconomics. 2010;28(5):395-409. doi: 10.2165/11531040-000000000-00000.
Osteoporosis is a condition marked by low bone mineral density and the deterioration of bone tissue. One of the main clinical and economic consequences of osteoporosis is skeletal fractures. To assess the healthcare and work loss costs of US patients with non-vertebral (NV) osteoporotic fractures. Privately insured (aged 18-64 years) and Medicare (aged >/=65 years) patients with osteoporosis (ICD-9-CM code: 733.0x) were identified during 1999-2006 using two claims databases. Patients with an NV fracture (femur, pelvis, lower leg, upper arm, forearm, rib or hip) were matched randomly on age, sex, employment status and geographic region to controls with osteoporosis and no fractures. Patient characteristics and annual healthcare costs were assessed over the year following the index fracture for privately insured (n = 4764) and Medicare (n = 48 742) beneficiaries (Medicare drug costs were estimated using multivariable models). Indirect (i.e. work loss) costs were calculated for a subset of privately insured, employed patients with available disability data (n = 1148). All costs were reported in $US, year 2006 values. In Medicare, mean incremental healthcare costs per NV fracture patient were $US13 387 ($US22 466 vs $US9079; p < 0.05). The most expensive patients had index fractures of the hip, multiple sites and femur (incremental costs of $US25 519, $US20 137 and $US19 403, respectively). Patients with NV non-hip (NVNH) fractures had incremental healthcare costs of $US7868 per patient ($US16 704 vs $US8836; p < 0.05). Aggregate annual incremental healthcare costs of NVNH patients in the Medicare research sample (n = 35 933) were $US282.7 million compared with $US204.1 million for hip fracture patients (n = 7997). Among the privately insured, mean incremental healthcare costs per NV fracture patient were $US5961 ($US11 636 vs $US5675; p < 0.05). The most expensive patients had index fractures of the hip, multiple sites and pelvis (incremental costs of $US13 801, $US9642 and $US8164, respectively). Annual incremental healthcare costs per NVNH patient were $US5381 ($US11 090 vs $US5709; p < 0.05). Aggregate annual incremental healthcare costs of NVNH patients in the privately insured sample (n = 4478) were $US24.1 million compared with $US3.5 million for hip fracture patients (n = 255). Mean incremental work loss costs per NV fracture employee were $US1956 ($US4349 vs $US2393; p < 0.05). Among patients with available disability data, work loss accounted for 29.5% of total costs per NV fracture employee. The cost burden of NV fracture patients to payers is substantial. Although hip fracture patients were more costly per patient in both Medicare and privately insured samples, NVNH fracture patients still had substantial incremental costs. Because NVNH patients accounted for a larger proportion of the fracture population, they were associated with greater aggregate incremental healthcare costs than hip fracture patients.
骨质疏松症是一种以骨密度低和骨组织恶化为特征的疾病。骨质疏松症的主要临床和经济后果之一是骨骼骨折。评估美国非脊柱(NV)骨质疏松性骨折患者的医疗保健和工作损失成本。使用两个索赔数据库,在 1999 年至 2006 年期间确定了患有骨质疏松症(ICD-9-CM 代码:733.0x)的私人保险(年龄 18-64 岁)和医疗保险(年龄>/=65 岁)患者。将 NV 骨折(股骨、骨盆、小腿、上臂、前臂、肋骨或臀部)患者随机匹配年龄、性别、就业状况和地理区域的对照组骨质疏松症和无骨折患者。评估私人保险(n = 4764)和医疗保险(n = 48742)受益人的索引骨折后一年的患者特征和年度医疗保健费用(使用多变量模型估计医疗保险药物成本)。对于有残疾数据的私人保险、在职患者的子集,计算了间接(即工作损失)成本(n = 1148)。所有成本均以美元报告,2006 年的价值。在医疗保险中,每例 NV 骨折患者的医疗保健增量成本为 13387 美元(22466 美元比 9079 美元;p<0.05)。最昂贵的患者有髋部、多处和股骨的指数骨折(增量成本分别为 25519 美元、20137 美元和 19403 美元)。患有 NV 非髋部(NVNH)骨折的患者的患者有 7868 美元的增量医疗保健成本(每位患者 16704 美元比 8836 美元;p<0.05)。医疗保险研究样本(n = 35933)中 NVNH 患者的年度增量医疗保健成本总额为 2.827 亿美元,而髋部骨折患者(n = 7997)为 2.041 亿美元。在私人保险中,每例 NV 骨折患者的医疗保健增量成本为 5961 美元(11636 美元比 5675 美元;p<0.05)。最昂贵的患者有髋部、多处和骨盆的指数骨折(增量成本分别为 13801 美元、9642 美元和 8164 美元)。每年每例 NVNH 患者的医疗保健增量成本为 5381 美元(11090 美元比 5709 美元;p<0.05)。私人保险样本(n = 4478)中 NVNH 患者的年度增量医疗保健成本总额为 2410 万美元,而髋部骨折患者(n = 255)为 350 万美元。每年每例 NV 骨折员工的增量工作损失成本为 1956 美元(4349 美元比 2393 美元;p<0.05)。在有残疾数据的患者中,工作损失占每例 NV 骨折员工总成本的 29.5%。NV 骨折患者对支付者的成本负担很大。尽管在医疗保险和私人保险样本中,髋部骨折患者的每位患者成本更高,但 NVNH 骨折患者的增量成本仍然很高。由于 NVNH 患者占骨折人群的比例更大,因此与髋部骨折患者相比,他们与更大的增量医疗保健成本相关。
Pharmacoeconomics. 2010
Osteoporos Int. 2010-11-25
J Med Econ. 2014-5
J Manag Care Spec Pharm. 2017-4
J Med Econ. 2012-10-22
Pharmacoeconomics. 2010
J Manag Care Spec Pharm. 2016-11-21
BMC Public Health. 2024-12-18
BMC Musculoskelet Disord. 2024-5-14
J Orthop Trauma. 2024-1-1
Methods Mol Biol. 2008
Curr Med Res Opin. 2008-3
Value Health. 2007
J Bone Miner Res. 2007-3
Pharmacoeconomics. 2006
Osteoporos Int. 2005-12